News

Shares of the biotech Moderna were up on Wednesday, as the Trump administration’s shifting position on messenger RNA-based ...
Since first detected in 1996, the highly pathogenic H5N1 ‘bird influenza’ has been perennially widespread in wild birds and ...
HHS cancels $776M Moderna contract for avian flu vaccine, signaling a major change in vaccine research approach.
HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...
HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine ...
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. Learn more on MRNA stock here.
Seasonal flu vaccine: In June, Moderna announced positive Phase 3 efficacy results for its seasonal flu vaccine (mRNA-1010), which demonstrated superior relative vaccine efficacy that was 26.6% ...
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of ...
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of ...
Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.